Tokyo Tape
Sign in
← PHC Holdings

Quarterly report · Q2

6523.TEDINET S100PICM
Period2022-04-01 → 2022-09-30
Filed2022-11-09
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥170.6bn2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥89.1bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Revenue¥340.5bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥166.1bn2021-04-01 → 2021-09-30Cons.Revenue IFRS
Revenue¥85.1bn2021-07-01 → 2021-09-30dCons.Revenue IFRS
Operating income¥10.5bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥8.5bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Operating income¥13.5bn2021-04-01 → 2021-09-30Cons.Operating profit loss IFRS
Operating income¥7.9bn2021-07-01 → 2021-09-30dCons.Operating profit loss IFRS
Profit before tax¥3.4bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥9.7bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Profit before tax¥3.0bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥20.1bn2021-04-01 → 2021-09-30Cons.Profit loss before tax IFRS
Profit before tax¥6.0bn2021-07-01 → 2021-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥1.2bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥8.3bn2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥8.5bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥15.0bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥4.6bn2021-07-01 → 2021-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥1.4bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥8.5bn2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Net income¥15.1bn2021-04-01 → 2021-09-30Cons.Profit loss IFRS
Net income¥4.6bn2021-07-01 → 2021-09-30dCons.Profit loss IFRS
Total assets¥596.3bnat 2022-09-30Cons.Assets IFRS
Total assets¥591.3bnat 2022-03-31Cons.Assets IFRS
Total assets¥569.2bnat 2021-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥446.9bnat 2022-09-30Cons.Liabilities IFRS
Total liabilities¥455.3bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥149.3bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥136.1bnat 2022-03-31Cons.Equity IFRS
Net assets / equity¥124.1bnat 2021-09-30Cons.Equity IFRS
Net assets / equity¥107.6bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥148.3bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥135.4bnat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥123.5bnat 2021-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥73.7bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥95.2bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥59.6bnat 2021-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥60.8bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥5.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥51.1bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥20.3bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥8.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥12.5bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥6.8bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥20.6bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥7.0bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥14.8bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥9.612022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥66.62022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥-70.782021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥129.062021-04-01 → 2021-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥39.672021-07-01 → 2021-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥9.522022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥65.982022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥-70.782021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥125.012021-04-01 → 2021-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥38.422021-07-01 → 2021-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio24.9%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio22.9%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio21.7%at 2021-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30¥1.1bn
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-09-30¥1.1bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥9.4bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue2022-04-01 → 2022-09-30¥55.4bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue external2022-04-01 → 2022-09-30¥55.4bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentsegment profit2022-04-01 → 2022-09-30¥12.0bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue2022-04-01 → 2022-09-30¥49.3bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue external2022-04-01 → 2022-09-30¥49.3bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentsegment profit2022-04-01 → 2022-09-30¥2.7bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue2022-04-01 → 2022-09-30¥64.8bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue external2022-04-01 → 2022-09-30¥64.8bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentsegment profit2022-04-01 → 2022-09-30¥5.3bn
—segment totalrevenue2022-04-01 → 2022-09-30¥169.5bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥169.5bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥20.0bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30¥1.4bn
Reconciling Itemsreconcilingrevenue external2021-04-01 → 2021-09-30¥1.4bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥8.8bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue2021-04-01 → 2021-09-30¥53.7bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue external2021-04-01 → 2021-09-30¥53.7bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentsegment profit2021-04-01 → 2021-09-30¥10.5bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue2021-04-01 → 2021-09-30¥44.0bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue external2021-04-01 → 2021-09-30¥44.0bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentsegment profit2021-04-01 → 2021-09-30¥3.0bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue2021-04-01 → 2021-09-30¥66.9bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue external2021-04-01 → 2021-09-30¥66.9bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentsegment profit2021-04-01 → 2021-09-30¥8.8bn
—segment totalrevenue2021-04-01 → 2021-09-30¥164.6bn
—segment totalrevenue external2021-04-01 → 2021-09-30¥164.6bn
—segment totalsegment profit2021-04-01 → 2021-09-30¥22.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 976
ItemContextValueUnit
Equity IFRSCurrentQuarterInstant_EquityAttributableToOwnersOfParentIFRSMember148323000000JPY
Equity IFRSCurrentQuarterInstant_NonControllingInterestsIFRSMember1013000000JPY
Equity IFRSCurrentQuarterInstant149337000000JPY
Profit loss before tax IFRSPrior1YTDDuration20148000000JPY
Profit loss before tax IFRSCurrentYTDDuration3395000000JPY
Depreciation expense ope cf IFRSPrior1YTDDuration15656000000JPY
Depreciation expense ope cf IFRSCurrentYTDDuration14809000000JPY
Impairment losses reversal of impairment losses ope cf IFRSPrior1YTDDuration-83000000JPY
Impairment losses reversal of impairment losses ope cf IFRSCurrentYTDDuration257000000JPY
Gain loss from financial assets measured at fair value through profit or loss ope cf IFRSPrior1YTDDuration-7759000000JPY
Gain loss from financial assets measured at fair value through profit or loss ope cf IFRSCurrentYTDDuration2944000000JPY
Interest expenses ope cf IFRSPrior1YTDDuration1073000000JPY
Interest expenses ope cf IFRSCurrentYTDDuration3217000000JPY
Share of loss profit of investments accounted for using equity method ope cf IFRSPrior1YTDDuration74000000JPY
Share of loss profit of investments accounted for using equity method ope cf IFRSCurrentYTDDuration265000000JPY
Loss gain on sale of fixed assets ope cf IFRSPrior1YTDDuration-13000000JPY
Loss gain on sale of fixed assets ope cf IFRSCurrentYTDDuration-8000000JPY
Decrease increase in trade receivables ope cf IFRSPrior1YTDDuration2972000000JPY
Decrease increase in trade receivables ope cf IFRSCurrentYTDDuration6012000000JPY
Decrease increase in inventories ope cf IFRSPrior1YTDDuration-3384000000JPY
Decrease increase in inventories ope cf IFRSCurrentYTDDuration-4059000000JPY
Increase decrease in trade payables ope cf IFRSPrior1YTDDuration-3432000000JPY
Increase decrease in trade payables ope cf IFRSCurrentYTDDuration-6794000000JPY
Increase decrease in retirement benefit liability ope cf IFRSPrior1YTDDuration-2000000JPY
Increase decrease in retirement benefit liability ope cf IFRSCurrentYTDDuration53000000JPY
Other changes in working capital ope cf IFRSPrior1YTDDuration455000000JPY
Other changes in working capital ope cf IFRSCurrentYTDDuration-4665000000JPY
Subtotal ope cf IFRSPrior1YTDDuration25706000000JPY
Subtotal ope cf IFRSCurrentYTDDuration15429000000JPY
Interest and dividends received ope cf IFRSPrior1YTDDuration329000000JPY
Interest and dividends received ope cf IFRSCurrentYTDDuration267000000JPY
Interest paid ope cf IFRSPrior1YTDDuration-1676000000JPY
Interest paid ope cf IFRSCurrentYTDDuration-1836000000JPY
Income taxes paid ope cf IFRSPrior1YTDDuration-4115000000JPY
Income taxes paid ope cf IFRSCurrentYTDDuration-8771000000JPY
Income taxes refund ope cf IFRSPrior1YTDDuration11000000JPY
Income taxes refund ope cf IFRSCurrentYTDDuration366000000JPY
Net cash provided by used in operating activities IFRSPrior1YTDDuration20254000000JPY
Net cash provided by used in operating activities IFRSCurrentYTDDuration5455000000JPY
Purchase of property plant and equipment and intangible assets inv cf IFRSPrior1YTDDuration-6685000000JPY
Purchase of property plant and equipment and intangible assets inv cf IFRSCurrentYTDDuration-5677000000JPY
Proceeds from sale of property plant and equipment and intangible assets inv cf IFRSPrior1YTDDuration54000000JPY
Proceeds from sale of property plant and equipment and intangible assets inv cf IFRSCurrentYTDDuration63000000JPY
Payments for loans receivable inv cf IFRSPrior1YTDDuration-601000000JPY
Payments for loans receivable inv cf IFRSCurrentYTDDuration－JPY
Payments for acquisition of subsidiaries inv cf IFRSPrior1YTDDuration－JPY
Payments for acquisition of subsidiaries inv cf IFRSCurrentYTDDuration-1798000000JPY
Payments for acquisition of businesses inv cf IFRSPrior1YTDDuration-330000000JPY
Payments for acquisition of businesses inv cf IFRSCurrentYTDDuration－JPY
Proceeds from sale of businesses inv cf IFRSPrior1YTDDuration700000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2021-07-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass